Concord Biotech reported a consolidated net profit of Rs 69.57 crore for the September 2026 quarter, marking a sequential rise from Rs 57.70 crore. Revenue from operations climbed to Rs 309.07 crore. Crucially, the company has confirmed November 4, 2026, as the record date for its 1:1 bonus share issue. Investors should note these positive growth metrics alongside the recent board committee restructuring.
Concord Biotech Q2 Profit Rises; 1:1 Bonus Record Date Confirmed
Revenue reached Rs 309.07 crore for the quarter ended September 30, 2026, with a net profit of Rs 69.57 crore.
Reader Takeaway: Sequential growth in earnings highlights operational momentum, while the upcoming bonus issue remains a key shareholder event.
What just happened
Concord Biotech has released its financial results for the second quarter of FY2027, reporting strong sequential growth. Revenue from operations rose to Rs 309.07 crore from Rs 257.49 crore in the previous quarter. Net profit after tax stood at Rs 69.57 crore, compared to Rs 57.70 crore in the June 2026 quarter. Additionally, the company formalized the record date for its 1:1 bonus share issuance for November 4, 2026.
Why this matters
The financial uptick reflects steady demand for the company’s pharmaceutical manufacturing portfolio. The confirmation of the bonus record date provides long-term shareholders with a concrete timeline for their upcoming share allotment. Reconstituted board committees, including the Audit and Risk Management groups, signal a refreshed approach to internal governance.
What changes now
Shareholders holding stock as of November 4, 2026, will be eligible for the 1:1 bonus. Post-allotment, the company’s equity base will double, which typically increases liquidity in the secondary market. The management continues to focus on a single operating segment in pharmaceuticals, streamlining operational reporting.
Context metrics
Basic Earnings Per Share (EPS) for the September 2026 quarter reached Rs 6.65, up from Rs 5.52 in the preceding quarter. The company also confirmed it is monitoring regulatory updates regarding national Labour Codes following an earlier exceptional liability provision of Rs 3.28 crore reported in the prior fiscal year.
What to track next
Investors should monitor the impact of the Celliimune Biotech Private Limited acquisition on future quarters. Further, observing how the newly formed board committees influence strategic decision-making will be vital for long-term governance tracking.